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Highlights
● Activation of NF-κB signaling in mesenchymal cells is
common in LR-MDS.
● Activation of NF-κB in mesenchymal cells leads to
transcriptional overexpression of inﬂammatory factors
including negative regulators of hematopoiesis.
● Activation of NF-κB attenuates HSPC numbers and
function ex vivo.
Myelodysplastic syndromes (MDS) are clonal disorders
characterized by ineffective hematopoiesis and the pro-
pensity for leukemic transformation. Cumulating evidence
has challenged the traditional view that MDS is exclusively
driven by hematopoietic cell intrinsic factors. Mesenchymal
cells in the bone marrow (BM) microenvironment have
emerged as key players in disease pathogenesis, as either
initiating or contributing factors [1–4]. We have earlier
demonstrated that the transcriptional landscape of highly
puriﬁed mesenchymal elements from human low-risk MDS
(LR-MDS) is distinct from normal mesenchymal cells and
characterized by cellular stress and the upregulation of
inﬂammatory molecules with known inhibitory effects on
normal hematopoiesis [4]. Speciﬁcally, mesenchymal
overexpression of the alarmins S100A8/9 was shown to
drive genotoxic stress in hematopoietic stem/progenitor
cells (HSPCs) and is related to leukemic evolution in a
subset of LR-MDS patients [3]. An important question
emerging from these ﬁndings is the nature of the upstream
drivers of cellular stress and inﬂammatory programs in LR-
MDS mesenchyme. Here, we show that activation of NF-κB
in mesenchymal cells is common in LR-MDS, driving
transcriptional activation of inﬂammatory programs and
attenuating HSPC function.
We earlier reported on the elucidation of the tran-
scriptome of highly puriﬁed mesenchymal cells isolated
from LR-MDS patients (n= 45) by massive parallel RNA
sequencing [3], suggesting inﬂammation in these
mesenchymal elements. In order to identify candidate
master regulatory pathways upstream of inﬂammatory
programs in LR-MDS, we performed Gene Set Enrichment
Analysis (GSEA) comparing the transcriptomes of these 45
patients to mesenchymal cells puriﬁed from healthy controls
(n= 10) [4]. In total, 120 gene signatures were signiﬁcantly
enriched in the LR-MDS mesenchyme, while 8 signatures
were enriched in normal mesenchymal cells. Among the
signatures upregulated in LR-MDS patients was a remark-
able abundance of signatures related to the activation of the
nuclear factor-kappa B (NF-κB) family of transcription
factors (Fig. 1a, b). To corroborate the notion of activation
of this pathway and provide better insight into the hetero-
geneity within the population, we assessed the expression
levels of NF-κB inhibitor NFKBIA (also known as IκB-ɑ),
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which forms an autoregulatory loop with activated NF-κB
transcription factors and therefore directly reﬂects activation
of NF-κB signaling [5, 6]. Overexpression of NFKBIA was
found in the majority of patients, suggesting that
mesenchymal NF-κB activation is a common feature in LR-
MDS (Fig. 1c). To conﬁrm the functional activation of NF-
κB in mesenchymal elements in LR-MDS, we demonstrated
increased phosphorylation of p65, a component of the
Z. Ping et al.
activated NF-κB complex, in intramedullary located CD271
+ mesenchymal cells (Fig. 1d) as well as in bone-lining
CD271+ stromal cells (Fig. 1e, f). Moreover, pathway
analysis (GSEA) conﬁrmed the transcriptional activation of
NF-κB signaling in patients with increased NFKBIA
expression in their mesenchymal niche cells (Figure S1A
and S1B). NFKBIA expression was signiﬁcantly correlated
with the expression of inﬂammatory cytokines and negative
regulators of hematopoiesis, which are bona ﬁde NF-κB
downstream targets such as IL6, IL8, and CCL3 (Fig-
ure S1C). No correlation was found between NFKBIA
expression and expression of S100A8 or S100A9 (spearman
correlation −0.11 and −0.22; P-adjusted 0.62 and 0.28,
respectively). Patients with activated NF-κB signaling
(NFKBIA+) in mesenchymal niche cells had no signiﬁcant
difference in overall or progression-free survival in com-
parison to the NFKBIA− subset (Figure S2A and S2B) in
this cohort of uniformly treated LR-MDS patients [4]. No
signiﬁcant correlations were found between mutational
status and activation of NF-κB signaling in mesenchymal
cells (Figure S2C).
While the genes encoding inﬂammatory factors and
negative regulators of hematopoiesis [4] are bona ﬁde
downstream targets of NF-κB signaling in other experi-
mental settings, we next wanted to provide experimental
support for the view that NF-κB activation speciﬁcally in
mesenchymal precursor cells results in upregulation of these
targets. To this end, we designed a strategy of activating
NF-κB signaling in mesenchymal progenitor cells by stably
overexpressing the constitutively active form of IKK2
(FLAG-IKK2SE), a kinase upstream regulator of NF-κB,
via a lentiviral vector (Fig. 2a, Figure S3A-C) [7] in OP9
cells. OP9 cells, like CD271+ cells [4], express osteolineage
commitment markers as well as HSPC regulatory factors
and robustly support the expansion of human HSPCs [8].
NF-κB activation in OP9 cells resulted in overexpression of
NFKBIA (Fig. 2c) and canonical NF-κB downstream
negative regulators of hematopoiesis, including Il6, Cxcl2
(murine homolog of IL8), Ccl3, Inhba, Fth1, Ltf, Ccl5, and
Cxcl4 (Fig. 2b), recapitulating the ﬁndings in LR-MDS
patients. Similar to the results in OP9 cells, activation of
NF-κB in human mesenchymal cells (HS5 cell line and
expanded bone-marrow-derived primary mesenchymal
cells) (Figure S3D) also resulted in upregulation of NF-κB
downstream targets including negative regulators of hema-
topoiesis such as IL6, IL8, CCL3, S100A9, INHBA, and
CCL5 (Figure S3E). Together, the data link the transcrip-
tional landscape of inﬂammatory alterations in mesenchy-
mal cells to activation of NF-κB in LR-MDS.
As earlier reported, in human MDS, the majority of
CD34+ HSPCs is in direct contact with CD271+ mesench-
ymal cells [9]. To assess the effect of NF-κB activation in
mesenchymal cells on the biology of normal HSPCs, we
performed co-culture experiments with bone marrow CD34+
HSPCs and OP9 cells transduced with IKK2SE or empty
vector (EV) (Fig. 2d). Co-culture for 7 days on IKK2SE-
transduced OP9 cells resulted in signiﬁcantly reduced
numbers of immunophenotypically deﬁned HSPCs in com-
parison to EV-transduced mesenchymal cells (Fig. 2d). In
addition, reduced HSPC number was reﬂected in a reduced
number of CFU-Cs (Fig. 2e), indicating attenuation of pro-
genitor function in this setting. NF-κB activation resulted in
impaired proliferation of mesenchymal cells in serum-
containing culture conditions (Figure S4A) which may
contribute to the reduced support for HSPCs in vitro
(Fig. 2d, left panel). However, equalizing mesenchymal cell
numbers by arresting their proliferation (using irradiation
and maintenance in non-proliferative, serum free, culture
conditions) (Figure S4B) recapitulated the signiﬁcantly
reduced numbers of immunophenotypically deﬁned HSPCs
on IKK2SE-transduced OP9 cells in comparison to EV-
transduced mesenchymal cells (Fig. 2d, right panel). This
included the fraction enriched for long-term hematopoietic
stem cells (LT-HSCs) deﬁned by the markers CD34
+CD38−CD45RA−CD90+, multipotent progenitor (MPP;
CD34+CD38−CD45RA−CD90−), multilymphoid pro-
genitor (MLP; CD34+CD38−CD45RA+CD90−), as well as
primitive (CD34+CD38−) and committed CD34+CD38+
progenitor cells (Fig. 2d), indicating that mesenchymal NF-
κB signaling attenuates HSPC number and function, at least
partially, independent of its effect on mesenchymal cell
proliferation.
Collectively, in this brief communication, we demon-
strate that mesenchymal NF-κB activation is a common
Fig. 1 Activation of NF-κB-mediated signaling in LR-MDS
mesenchymal cells. a Representative GSEA plots demonstrating
activation of NF-κB signaling in mesenchymal cells from LR- MDS.
b Summary of gene sets implicating NF-κB activation in mesenchymal
cells from 45 LR-MDS patients. Gene set size, NES, and FDR value of
each gene set are as listed. GSEA gene sets enrichment analysis, NES
normalized enrichment score, FDR false discovery rate. c Gene
expression level (in FPKM) of NFKBIA in normal and LR-MDS
samples. d Representative images showing immunoﬂuorescence
staining of CD271 and phospho-p65 in both age-matched control (left
panel) and LR-MDS patient (right panel) bone marrow slides con-
ﬁrming activation of NF-κB in mesenchymal cells. The white arrow
indicates the absence or presence of nuclear phospho-p65 signal (red)
in CD271+ (green) mesenchymal cells. The nuclei were counterstained
with DAPI. e Representative photomicrographs of the distribution of
CD271+ mesenchymal cells (left panels). These cells are enriched at
the endosteal surface (marked by bone-lining area) and have a spindle-
shaped morphology. Representative immuno-histochemical analysis of
phospho-p65 (middle and right panels) in age-matched controls (top)
and LR-MDS (bottom) patients, demonstrating NF-κB activation in
spindle-shaped endosteal cells in LR-MDS. f The percentage of
phospho-p65+ bone-lining cells as a fraction of the total bone-lining
cells in LR-MDS (n= 4) compared to age-matched controls (n= 3).
***P < .001, *P < .05. FPKM fragments per kilobase of exon per
million fragments mapped; NFKBIA NF-kappa-B inhibitor alpha
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ﬁnding in LR-MDS patients leading to transcriptional
upregulation of inﬂammatory programs associated with
negative regulation of hematopoiesis and attenuation of
HSPC numbers and function.
Demonstration of mesenchymal activation of NF-κB
provides human disease relevance to a number of murine
studies implicating NF-κB activation in ancillary cells to the
pathogenesis of hematopoietic disease. NF-κB activation in
non-hematopoietic cells has been shown to induce ‘MDS-
like’ myeloproliferative disease (MPD) in mice [10]. In
another study, NF-κB activation in bone marrow
mesenchymal cells and endothelial cells, as a result of
elevated levels of the microRNA miR-155, generated a
persistent pro-inﬂammatory state of the bone marrow niche
leading to an MPD-like disease in a Notch/RBPJ loss-of-
function mouse model [11]. Our experimental data
demonstrate that NF-κB activation in the mesenchyme
attenuates normal hematopoiesis, which is of key relevance
to LR-MDS characterized by cytopenia. The implication of
mesenchymal NF-κB activation in the pathogenesis of MDS
may also point toward common mechanisms between the
pathogenesis of MDS and oncogenesis in other systems.
Fig. 2 Activated NF-κB signaling in mesenchymal cells attenuates
HSPC number and function. a Western blot analysis showing the
overexpression of Flag-IKK2SE and nuclear phospho-p65, the phos-
phorylated (active) form of NF-κB, in IKK2SE transduced OP9 cells
in comparison to empty vector (EV)-transduced or wild-type cells.
b Expression level of NF-κB downstream targets (Il6, Cxcl2) and
disease-relevant negative regulators of hematopoiesis [3, 4] in OP9
cells transduced with IKK2SE. Fold change relative to EV is presented
(n= 3 for each transcript). c Expression level of NFKBIA in OP9 cells
transduced with EV or IKK2SE and re-plated in serum-containing
medium for 2 or 5 days. Fold change relative to wildtype OP9 cells is
presented (n= 3). d Co-culture experiments with bone marrow CD34+
HSPCs and OP9 stromal cells transduced with either EV or IKK2SE.
The co-culture took place for 7 days before analysis. The absolute
number of immunophenotypically deﬁned HSPC subsets (Lin−CD34
+CD38+ progenitors, Lin−CD34+CD38− HSPCs, Lin−CD34+CD38
−CD45RA−CD90+ LT-HSCs, Lin−CD34+CD38−CD45RA−CD90−
MPPs, Lin−CD34+CD38−CD45RA+CD90−MLPs) on day 7 after co-
culturing with OP9-EV or OP9-IKK2SE, in serum-containing medium
condition (left panel) and serum-free, stem cell growth medium
(SCGM) condition with OP9-EV and OP9-IKK2SE irradiated at 30 Gy
(right panel). Data represent mean±SEM of two independent experi-
ments. e The total number of CFU-C after 7 days co-culture in serum-
containing medium condition (left panel) and serum-free medium
condition with OP9-EV and OP9-IKK2SE irradiated at 30 Gy (right
panel). Data represent mean±SEM of two independent experiments
performed in triplicate. Unpaired t-test was performed for statistical
analysis; ***P < .001, **P < .01, *P < .05
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NF-κB-mediated chronic tissue inﬂammation has been
shown to drive cancer initiation and progression via secre-
tion of cytokines and soluble factors in models of several
other forms of cancer [12, 13], including skin, prostate, and
colon cancer. In these models, activation of NF-κB signal-
ing, speciﬁcally in ﬁbroblasts, promoted malignant features
in heterotypic (pre)cancerous cells, supporting the hypoth-
esis that mesenchymal inﬂammation may facilitate tumor-
igenesis in the hematopoietic system as well.
The activation of NF-κB signaling in mesenchymal cells
in most LR-MDS patients raises intriguing questions about
the events driving this activation. This includes the question
whether mesenchymal cell-intrinsic alterations or extrinsic
events are driving NF-κB activation. While the answer to
this question remains speculative in the absence of experi-
mental evidence (and may vary between patients), it is
conceivable that primary alterations in hematopoietic ele-
ments drive activation of NF-κB activation in the
mesenchymal niche.
This notion is supported by recent ﬁndings where acti-
vation of the NF-κB pathway in CD34+ HSPCs is impli-
cated in MDS pathogenesis [14] and CD271+ mesenchymal
cells co-localize with CD34+ HSPCs in the bone marrow
section of MDS patients [9]. It is therefore reasonable to
hypothesize that activated NF-κB pathway in HSPCs sig-
nals to the adjacent mesenchymal elements, resulting in NF-
κB activation in mesenchymal cells. As NF-κB activation is
likely maintained through autocrine/paracrine feedback
signaling networks, other cellular types that anatomically
localize with the activated HSPCs and mesenchymal ele-
ments could be involved as well, suggesting that diverse
cellular components may participate in this crosstalk. The
combined ﬁndings suggest that in LR-MDS, activation of
NF-κB occurs in both hematopoietic and mesenchymal
cells, likely through autocrine and paracrine feedback sig-
naling networks, leading to a NF-κB-mediated inﬂamma-
tory milieu in the LR-MDS bone marrow and an
overexpression of a repertoire of secreted negative hema-
topoietic regulators. S100A8/9, recently shown by us to
induce NF-κB activation and genotoxic stress in HSPCs and
to be associated with an increased likelihood of leukemic
transformation, was not correlated with NFKBIA expression
in patients, indicating that its regulation is more complex
and may include upstream TP53 activation [3].
Taken together, the ﬁndings support the notion that
mesenchymal factors, in addition to hematopoietic cell
autonomous characteristics, may be therapeutically targeted
in LR-MDS and warrant ongoing experiments deﬁning the
contribution of NF-κB activation and inﬂammation to
ineffective hematopoiesis and leukemic evolution in MDS.
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